STOCK TITAN
  1. Home
  2. News
  3. INZY

Inozyme Pharma Inc - INZY STOCK NEWS

Welcome to our dedicated news page for Inozyme Pharma (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inozyme Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inozyme Pharma's position in the market.

News
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Rhea-AI Summary
Inozyme Pharma, Inc. (INZY) announces positive safety and efficacy data for INZ-701 in ABCC6 and ENPP1 Deficiency. The company shows promising results in vascular pathology, visual function, and patient-reported outcomes. The press release highlights the potential benefits of INZ-701 in treating genetic diseases. Notable improvements were observed in clinical markers, including carotid intima-media thickness, choroidal thickness, visual function, and global impression of change. The company plans to initiate a pivotal trial for pediatric ABCC6 Deficiency in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.42%
Tags
clinical trial
-
News
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Inozyme Pharma, Inc. (INZY) granted stock options to three new employees under its 2023 Inducement Stock Incentive Plan. The options allow the purchase of up to 80,000 shares at an exercise price of $6.93 per share. The options have a 10-year term and vest over four years, with 25% of shares vesting on the first anniversary and monthly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.42%
Tags
none
-
News
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Inozyme Pharma, Inc. (INZY) announces CEO's participation in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on developing therapeutics for rare diseases. The event will be live webcasted and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
conferences
News
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Rhea-AI Summary
Inozyme Pharma, Inc. (Nasdaq: INZY) will host a conference call and webcast on April 8, 2024, to discuss topline data from Phase 1/2 trials of INZ-701 for ABCC6 and ENPP1 Deficiency. Key opinion leaders will present on ABCC6 Deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.83%
Tags
conferences clinical trial
-
News
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
Rhea-AI Summary
Inozyme Pharma, Inc. (INZY) reports financial results for 2023 and highlights progress in clinical trials and patient registries. Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected soon. The Company launches a global patient registry in partnership with GACI Global to advance understanding of rare diseases. Financially, Inozyme is well-funded into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
earnings
-
News
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma, Inc. (INZY), to participate in an Orphan Bone & Neuromuscular Diseases panel presentation at the TD Cowen 44th Annual Health Care Conference. The event will take place on March 4, 2024, from 9:10-10:10am ET, with a live webcast accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.01%
Tags
conferences
News
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Inozyme Pharma, Inc. has granted stock options to four new employees to purchase shares of the Company’s common stock. The options have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee’s start date and 2.0833% of the shares underlying the option vesting monthly thereafter. The exercise price is $5.64 per share, based on the closing price per share of the Company’s common stock on February 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
News
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Inozyme Pharma, Inc. (Nasdaq: INZY) granted stock options to a new employee under the 2023 Inducement Stock Incentive Plan. The company's compensation committee granted nonstatutory stock options to purchase up to 65,000 shares of the Company’s common stock at an exercise price of $3.85 per share, with a 10-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
-
News
Inozyme Pharma to Participate in Upcoming Investor Conferences
Rhea-AI Summary
INZY: Inozyme Pharma CEO to Present at Investor Conferences in November 2023. The company's CEO, Douglas A. Treco, Ph.D., will participate in two upcoming investor conferences, including The Jefferies London Healthcare Conference and The Piper Sandler 35th Annual Healthcare Conference. Live webcasts and replays will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
conferences
News
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Rhea-AI Summary
Inozyme Pharma, Inc. reports financial results for Q3 2023, highlighting the progress of INZ-701 in pediatric and adult patients with ENPP1 Deficiency and ABCC6 Deficiency, with topline data expected in 2024 and 2025. Cash position remains strong at $192.4 million, funding operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
earnings
Stock INZY logo
Inozyme Pharma Inc

Nasdaq:INZY

INZY Rankings

#3515 Ranked by Market Cap
#356 Ranked by Stock Gains
N/A Ranked by Dividends

INZY Stock Data

317.51M
34.13M
0.66%
92.95%
4.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About INZY

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development.